标题
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-03-08
DOI
10.3389/fphar.2021.632677
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes
- (2021) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- (2021) Romina Libster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies
- (2020) Mohamed Elmeliegy et al. CLINICAL PHARMACOKINETICS
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus–A Possible Reference for Coronavirus Disease‐19 Treatment Option
- (2020) Tian‐Tian Yao et al. JOURNAL OF MEDICAL VIROLOGY
- Emerging coronaviruses: Genome structure, replication, and pathogenesis
- (2020) Yu Chen et al. JOURNAL OF MEDICAL VIROLOGY
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus
- (2020) Steven S. Good et al. PLoS One
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
- (2020) Timothy P. Sheahan et al. Nature Communications
- Remdesivir as a possible therapeutic option for the COVID-19
- (2020) Jaffar A. Al-Tawfiq et al. Travel Medicine and Infectious Disease
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Xueting Yao et al. CLINICAL INFECTIOUS DISEASES
- Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
- (2020) N. Lian et al. CLINICAL MICROBIOLOGY AND INFECTION
- Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19
- (2020) Bharat Damle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- COVID-19 and Multiorgan Response
- (2020) Sevim Zaim et al. CURRENT PROBLEMS IN CARDIOLOGY
- Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
- (2020) Dan Yan et al. EUROPEAN RESPIRATORY JOURNAL
- The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients
- (2020) Jing Yuan et al. INFLAMMATION RESEARCH
- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
- (2020) Christian A. Devaux et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Emergency Use Authorization of Remdesivir
- (2020) Michael G. Ison et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- (2020) Eli S. Rosenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lopinavir pharmacokinetics in COVID-19 patients
- (2020) Matthieu Gregoire et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin
- (2020) Anwarul Hasan et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
- (2020) Zhen Zhu et al. JOURNAL OF INFECTION
- Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
- (2020) Lisi Deng et al. JOURNAL OF INFECTION
- Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
- (2020) Chien-Yu Cheng et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Treatment options for COVID-19: The reality and challenges
- (2020) Shio-Shin Jean et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Comorbidities and multi-organ injuries in the treatment of COVID-19
- (2020) Tianbing Wang et al. LANCET
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- (2020) Kai Duan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19)
- (2020) Tanja R. Zijp et al. THERAPEUTIC DRUG MONITORING
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
- (2020) Wei Tang et al. BMJ-British Medical Journal
- Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
- (2020) Nicholas J. Mercuro et al. JAMA Cardiology
- The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
- (2020) Xi Wang et al. Cell Discovery
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- (2020) Jia Liu et al. Cell Discovery
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission—A Preliminary Report of a Retrospective Cohort Study
- (2020) Jin-nong Zhang et al. Current Medical Science
- Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy
- (2020) JM. Scherrmann AAPS Journal
- Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion
- (2020) Xinyi Xia et al. BLOOD
- Use of convalescent plasma in hospitalized patients with COVID-19: case series
- (2020) Livia Hegerova et al. BLOOD
- Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis
- (2020) Wei Liu et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Lopinavir-ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia
- (2020) Christophe Beyls et al. Circulation-Arrhythmia and Electrophysiology
- Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors
- (2020) Emiel Leegwater et al. CLINICAL INFECTIOUS DISEASES
- Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
- (2020) Anya Jafari et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Ribavirin therapy for severe COVID-19: a retrospective cohort study
- (2020) Song Tong et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
- (2020) Samia Arshad et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients
- (2020) Minh Patrick Lê et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
- (2020) Dong Huang et al. JOURNAL OF MEDICAL VIROLOGY
- Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients
- (2020) Michael J. Joyner et al. MAYO CLINIC PROCEEDINGS
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence
- (2020) Myron S. Cohen NEW ENGLAND JOURNAL OF MEDICINE
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
- (2020) Alexandre B. Cavalcanti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials
- (2020) Mekonnen Sisay PHARMACOLOGICAL RESEARCH
- Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
- (2020) Hassan Abolghasemi et al. TRANSFUSION AND APHERESIS SCIENCE
- Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients
- (2020) Mario Karolyi et al. WIENER KLINISCHE WOCHENSCHRIFT
- Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
- (2020) Victoria C. Yan et al. ACS Medicinal Chemistry Letters
- Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
- (2020) Andrea J. Pruijssers et al. Cell Reports
- No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
- (2020) Yin-Qiu Huang et al. Frontiers in Pharmacology
- Comorbidity Assessment Is Essential During COVID-19 Treatment
- (2020) Shweta Jakhmola et al. Frontiers in Physiology
- COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
- (2020) Muhammad Adnan Shereen et al. Journal of Advanced Research
- Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
- (2020) Tatsuhiko Wada et al. Frontiers in Medicine
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- (2020) Mayla Gabriela Silva Borba et al. JAMA Network Open
- Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
- (2020) E. Susan Amirian et al. One Health
- Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19)
- (2020) Peter A. McCullough ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
- (2020) Thibault Fiolet et al. CLINICAL MICROBIOLOGY AND INFECTION
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
- (2020) Gholamali Eslami et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
- (2020) Robert L. Hoffman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2020) Peter W Horby et al. LANCET
- Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
- (2020) Remo H M Furtado et al. LANCET
- Observational study of azithromycin in hospitalized patients with COVID-19
- (2020) Alejandro Rodríguez-Molinero et al. PLoS One
- Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases
- (2020) Michael K. Lo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
- (2020) Suzanne J. F. Kaptein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
- (2020) Ludovico Cantuti-Castelvetri et al. SCIENCE
- Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
- (2020) Dhan Bahadur Shrestha et al. Virology Journal
- Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”
- (2020) Aimé Bonny et al. Travel Medicine and Infectious Disease
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
- (2020) Anup Agarwal et al. BMJ-British Medical Journal
- Covid-19: US approves remdesivir despite WHO trial showing lack of efficacy
- (2020) Elisabeth Mahase BMJ-British Medical Journal
- Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters
- (2020) Slobodan Rendic et al. CURRENT DRUG METABOLISM
- The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the ‘Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19’
- (2020) Giovanna Liuzzo et al. EUROPEAN HEART JOURNAL
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
- (2020) Anna Moniuszko-Malinowska et al. Journal of Clinical Medicine
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
- (2019) Ariane J. Brown et al. ANTIVIRAL RESEARCH
- An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease
- (2018) Yong Wah Tan et al. ANTIVIRAL RESEARCH
- MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells
- (2018) Yu Cong et al. PLoS One
- The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies
- (2018) B.G. Murphy et al. VETERINARY MICROBIOLOGY
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
- (2018) Maria L. Agostini et al. mBio
- The Antiviral Drug Arbidol Inhibits Zika Virus
- (2018) Susan L. Fink et al. Scientific Reports
- Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model
- (2018) Andrea Galli et al. Scientific Reports
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice
- (2017) Chunfeng Li et al. EBioMedicine
- Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials
- (2016) Vincent Madelain et al. CLINICAL PHARMACOKINETICS
- Structure, Function, and Evolution of Coronavirus Spike Proteins
- (2016) Fang Li Annual Review of Virology
- Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
- (2016) Jonathan Shuter Therapeutics and Clinical Risk Management
- Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever
- (2015) Brian B. Gowen et al. ANTIVIRAL RESEARCH
- Arbidol as a broad-spectrum antiviral: An update
- (2014) Julie Blaising et al. ANTIVIRAL RESEARCH
- Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells
- (2014) Aline Schögler et al. EUROPEAN RESPIRATORY JOURNAL
- Development of Novel Potent Orally Bioavailable Oseltamivir Derivatives Active against Resistant Influenza A
- (2014) Dennis Schade et al. JOURNAL OF MEDICINAL CHEMISTRY
- Favipiravir (T-705), a novel viral RNA polymerase inhibitor
- (2013) Yousuke Furuta et al. ANTIVIRAL RESEARCH
- Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
- (2013) Darryl Falzarano et al. NATURE MEDICINE
- Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides
- (2012) Aesop Cho et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans
- (2012) S. van Boheemen et al. mBio
- Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice
- (2009) E. Keyaerts et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Susceptibility of Highly Pathogenic H5N1 Influenza Viruses to the Neuraminidase Inhibitor Oseltamivir Differs In Vitro and in a Mouse Model
- (2009) E. A. Govorkova et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ribavirin Reduces Mortality in Enterovirus 71–Infected Mice by Decreasing Viral Replication
- (2008) Zhao‐Hong Li et al. JOURNAL OF INFECTIOUS DISEASES
- In vitro efficacy of ribavirin against canine distemper virus
- (2007) Gabriella Elia et al. ANTIVIRAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started